The Israeli-owned device maker's China facility begins producing its Alma Rejuve platform, reducing supply-chain risk and supporting regional expansion.
Sisram Medical announced that its China manufacturing facility has commenced operations, with the first Alma Rejuve units rolling off the line. Alma Rejuve is a multipurpose energy platform combining RF microneedling, ultrasound, and other modalities for skin tightening and resurfacing.
Local manufacturing in China reduces supply-chain vulnerability and lowers landed cost for regional distribution—critical as aesthetic device demand accelerates in Asia-Pacific markets. For U.S. and European practices, this signals Sisram's commitment to scale production and potentially improve delivery timelines and pricing competitiveness against InMode, Cutera, and other established players.
China facility begins Alma Rejuve production; supply-chain localization reduces cost and delivery risk.
The move also suggests Sisram is hedging against tariff and logistics pressures affecting device imports. Practices should monitor whether localized production translates to improved availability or pricing in their markets over the next 12–18 months.
Source: original report ↗
Free alerts Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
